Home > Haematology > EHA 2020 > Graft-Versus-Host Disease > Ruxolitinib improves steroid-refractory aGVHD across subtypes

Ruxolitinib improves steroid-refractory aGVHD across subtypes

Presented By
Prof. Robert Zeiser, University Hospital Freiburg, Germany
EHA 2020
Phase 3, REACH2
Ruxolitinib demonstrated superiority to standard therapy across subtypes in a phase 3 trial of patients with steroid-refractory acute graft-versus-host disease (aGVHD). Prof. Robert Zeiser (University Hospital Freiburg, Germany) presented a follow-up analysis of the phase 3 REACH2 trial [1], which was published last month in the New England Journal of Medicine [2]. In the published analysis, ruxolitinib improved outcomes in patients (n=309) with steroid-refractory aGVHD after 28 days of treatment (62.3% vs 39.4%; P<0.001). In this follow-up analysis, Prof. Zeiser examined the therapy responses in different subgroups of patients of the REACH2 trial. Several subgroups of patients responded better to ruxolitinib than to standard therapy, including younger patients aged 18-65 years, patients with varying degrees of disease severity, or patients with...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on